Tag: privacy

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

Curated 5,500-Square-Foot Venue Launches June 14 Across from Chateau Marmont with Premium Brands, Gourmet Experiences, and Hollywood Design Flair

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Stingray (TSX: RAY. A; RAY.B), an industry leader in music and video content distribution, business services, and advertising solutions, proudly announces its contribution in the grand opening of BMO's new branch at CF Toronto Eaton Centre. This state-of-the-art, full-service branch features Stingray Business's cutting-edge digital signage solutions, highlighting the integration of advanced technology in customer experiences.

The BMO branch in the CF Toronto Eaton Centre is strategically located on the corner of Yonge and  Dundas near Sankofa Square, one of Toronto's busiest intersections and a vibrant hub of innovation and activity. Its two-story wraparound windows presented a unique opportunity to elevate BMO’s brand presence, showcase an innovative approach to marketing, while maintaining a welcoming and comfortable customer experience within the branch. To maximize this unique opportunity, BMO partnered with Stingray Business to implement an innovative digital signage solution.

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.